Amgen voluntary admission: failure to notify PMCPA/MHRA of new nominated signatories (AUTH/2719/6/14)

📊

Key facts

⌄

Case	AUTH/2719/6/14
Company	Amgen Limited
Issue	Failure to notify PMCPA and MHRA of two new non-medical nominated signatories; materials certified without compliant signatory notification arrangements
Applicable Code year	2014
Breach clauses	14.1 and 14.4
How identified	Routine review of promotional material; certificate showed a non-medical signatory and triggered check against notified list
Time period impacted	Approximately five months (January–June 2014)
Items impacted	34 promotional items (plus two additional materials no longer in use identified later)
Notification date	20 June 2014 (names/qualifications notified to PMCPA and MHRA)
Complaint received	20 June 2014 (PDF) / 26 June 2014 (website listing)
Case completed	21 July 2014
Appeal	No appeal
Sanctions	Undertaking received; additional sanctions not stated

Reviewed by Dr Anzal Qurbain (FFPM) — ABPI Final Signatory

🤖

Got a question about this case?

Ask one of our 13 specialist ABPI advisors — instant answers, 24/7.

Ask AskAnzal AI

📋

⌄

Amgen voluntarily admitted an administrative error: it did not notify the PMCPA and MHRA of two new non-medical nominated signatories.
As a result, for around five months (Jan–Jun 2014), promotional material was certified in a way that did not meet Code requirements (only one nominated signatory had been notified to PMCPA/MHRA).
Amgen identified the issue during a routine review of 2014 promotional material when a reviewer saw a certificate naming one of the non-medical signatories and checked whether they were on the notified list.
Amgen stopped further certification by the two signatories until notification was completed, then notified PMCPA and MHRA (names/qualifications notified on 20 June 2014).
Amgen reviewed impacted materials: it stated 34 promotional items were approved during the period and impacted; later it identified two additional materials no longer in use.
It arranged second-signatory certification for 15 current items (no content changes) and retrospective second-signatory review of 19 items no longer in use (considered Code compliant).
Amgen implemented process changes: internal compliance committee approval/minuted decisions for new signatories; compliance lead to notify PMCPA/MHRA and confirm completion; updated signatory list communicated to reviewers/approvers/admin support and uploaded to intranet.

⚖️

⌄

The Director treated the voluntary admission as a complaint under Paragraph 5.6 of the Constitution and Procedure.
The Panel ruled breaches of Clauses 14.1 and 14.4.
The Panel found that materials certified by signatories not notified in advance were not certified in accordance with the Code.
No appeal.

🔒

Members get the complete breakdown — Clauses, Sanction, Signatory Lens, Audit checklist, and 3 Key Questions.

Best value

£249/year

Annual — save £99

£29/mo

Monthly

Join Now — Instant Access